(Reuters) - An experimental drug from Biogen Idec Inc showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss.
The drug is also being tested in patients with multiple sclerosis, an inflammatory disease that attacks the protective covers of nerve cells. Current treatments focus on decreasing inflammation rather than regenerating cells. That study's results are due in 2016, the company said.
Also read: Qualcomm raises bid for NXP to about $43.22B